Evidence map›Paper›PMID 37981618›Full record

ArticleHormones (Athens, Greece)2024

Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly.

Gokcen Unal Kocabas, Banu Sarer Yurekli, Ilgin Yildirim Simsir, Su Ozgur, Murat Aksit, Giray Bozkaya

Abstract read
PubMed Publisher
In one paragraph

Article in Hormones (Athens, Greece), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gokcen Unal KocabasDivision of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey. gunalkocabas@gmail.com.ORCID http://orcid.org/0000-0002-1849-3179
Banu Sarer YurekliDivision of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey.ORCID http://orcid.org/0000-0003-1809-2655
Ilgin Yildirim SimsirDivision of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-6801-8499
Su OzgurEge University Translational Pulmonary Research Center, Regional Hub for Cancer Registration in North Africa, Central and Western Asia, WHO/IARC GICR, Izmir, Turkey.ORCID http://orcid.org/0000-0002-8993-674X
Murat AksitDepartment of Medical Biochemistry, Tepecik Training and Research Hospital, Izmir, Turkey.ORCID http://orcid.org/0000-0003-2106-9130
Giray BozkayaDepartment of Medical Biochemistry, Bozyaka Training and Research Hospital, Izmir, Turkey.ORCID http://orcid.org/0000-0002-5756-5796
Ege University · TRIzmir Bozyaka Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe OPG/RANKL (osteoprotegerin/receptor activator of nuclear factor kappa-B) system, which plays a crucial role in bone metabolism, is also associated with vascular calcification. Acromegaly is characterized by excessive secretion of growth hormone and insulin-like growth factor, and studies have demonstrated an elevated risk of cardiovascular disease in individuals with acromegaly. In this study, our objective was to investigate the relationship between OPG/RANKL and various cardiovascular risk scoring systems.

methodsWe recruited 44 consecutive acromegaly patients and 41 healthy controls with a similar age and gender distribution for this study.

resultsWhile RANKL levels were significantly higher in the acromegaly group compared to the controls, OPG levels were not found to be significantly different between the two groups. Furthermore, within the acromegaly group, RANKL levels were significantly higher in patients with active acromegaly compared to those with controlled acromegaly. Osteoprotegerin levels showed a positive correlation with the Framingham risk score (FRS) in the acromegaly group. Linear regression analysis revealed an association of OPG with FRS (adjusted R

conclusionOPG and RANKL may serve as potential markers for assessment of cardiovascular calcification and prediction of the cardiovascular risk status in acromegalic patients.

Indexed as

AcromegalyCardiovascular DiseasesHeart Disease Risk FactorsHumansOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa BRisk FactorsOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa BAcromegalyCardiovascular risk scoreOsteoprotegerinReceptor-activated nuclear factor kappa-B ligand

Identifiers

PMID37981618
OpenAlexW4388832735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.